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Background: Diabetes mellitus type 2 (DM2) is highly associated with increased risk for chronic kidney disease
(CKD), end stage renal disease (ESRD) and cardiovascular morbidity. Epidemiological and genetic studies generate
hypotheses for innovative strategies in DM2 management by unravelling novel mechanisms of diabetes
complications, which is essential for future intervention trials. We have thus initiated the DIAbetes COhoRtE study
(DIACORE).
Methods: DIACORE is a prospective cohort study aiming to recruit 6000 patients of self-reported Caucasian
ethnicity with prevalent DM2 for at least 10 years of follow-up. Study visits are performed in University-based
recruiting clinics in Germany using standard operating procedures. All prevalent DM2 patients in outpatient clinics
surrounding the recruiting centers are invited to participate. At baseline and at each 2-year follow-up examination,
patients are subjected to a core phenotyping protocol. This includes a standardized online questionnaire and
physical examination to determine incident micro- and macrovascular DM2 complications, malignancy and
hospitalization, with a primary focus on renal events. Confirmatory outcome information is requested from patient
records. Blood samples are obtained for a centrally analyzed standard laboratory panel and for biobanking of
aliquots of serum, plasma, urine, mRNA and DNA for future scientific use. A subset of the cohort is subjected to
extended phenotyping, e.g. sleep apnea screening, skin autofluorescence measurement, non-mydriatic retinal
photography and non-invasive determination of arterial stiffness.
Discussion: DIACORE will enable the prospective evaluation of factors involved in DM2 complication pathogenesis
using high-throughput technologies in biosamples and genetic epidemiological studies.
Keywords: Diabetes mellitus type 2, Diabetic nephropathy, Chronic kidney disease, End stage renal disease,
Cardiovascular morbidity, diabetes complications, Epidemiology, GeneticsBackground
Diabetes mellitus type 2 (DM2) is increasing in preva-
lence world wide, with more than 366 million people
worldwide expected to be affected by the year 2030 [1].
DM2 interacts with other major risk factors such as
hypertension and dyslipidemia, increasing the risk for
micro- and macrovascular morbidity such as chronic
kidney disease (CKD), end-stage renal disease (ESRD),* Correspondence: carsten.boeger@ukr.de
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reproduction in any medium, provided the oratherosclerosis, coronary heart disease and cerebral
ischemia [2-5]. For example, diabetic nephropathy is the
underlying kidney disease of about every third patient
starting renal replacement therapy [6-11].
In order to prevent cardio-renal complications among
DM2 patients, it is necessary to understand the factors
that influence their development. Hyperglycemia and
hypertension are predominant factors. In the past 20
years, interventional studies have led to the development
of effective strategies for improved blood pressure and
glucose control [12-18], but nevertheless renal events
such as microalbuminuria [12,14,19] and doubling ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with similar data for cardiovascular events.
This points towards other risk factors that add to the
development of cardio-renal complications of DM2.
Genetic factors appear to play an important role in renal
complications, as evidenced by significant heritability of
albuminuria and eGFR in diabetes patients [21]. Genetic
variants associated with risk for type 2 diabetes, microalbu-
minuria and reduced kidney function have recently been
identified [22-27], but most of the heritability observed in
family studies is still unexplained [28,29]. Thus, additional
genetic and non-genetic risk factors remain to be identified.
Key to the development of innovative strategies in
DM2 management is the availability of high quality
epidemiological study data.
In prospective general population-based studies [30,31],
the number of persons developing DM2-associated cardio-
renal events is limited. In contrast, a prospective cohort
focusing on DM2 patients enables the evaluation of a
broad range of DM2-specific risk factors for cardio-renal
complications in an unbiased fashion and the collection of
biosamples before and during the development of the
events. Furthermore, such a patient group targets persons
with an enhanced interest in participating in such a
study and thus ensuring excellent compliance and
high response during follow-up. However, large
cohorts of DM2 patients with prospective biosample
ascertainment are the exception [32-34].
Thus, we have initiated the DIAbetes COhoRtE study
(DIACORE), a large cohort study for long term prospective
follow-up with extensive biobanking. The aims of the
DIACORE study are to discover novel mechanisms
involved in the development and progression of dia-
betes complications, using modern high-throughput
technologies for the unbiased analysis of biosamples.
Here, we report the study design.
Methods
Study design and main objective
DIACORE is a prospective cohort study aiming to elucidate
mechanisms involved in the development and progression
of DM2 complications using high-throughput technologies
in collected biosamples (transcriptomics, proteomics and
metabolomics), and genetic epidemiological studies inclu-
ding genome-wide association studies. Beginning 2/2010,
the study aims to recruit 6000 patients with prevalent DM2
in a 4 year period. A standardized core phenotyping proto-
col including interview and medical examinations is
performed at baseline and at every 2-year follow-up visit,
with long-term follow-up of at least 10 years planned.
Written informed consent is obtained after a standardized
consent discussion at baseline. Blood samples are obtained
from patients for a centrally analyzed standard laboratory
panel and for biobanking of serum, plasma, urine, mRNAand DNA. Preferably, patients are fasting for at least
eight hours at each visit. Patients are then subjected
to a standardized physical examination and online
questionnaire by specifically trained study nurses in
the DIACORE examination rooms at the University based
recruitment centers. In addition to the core phenotyping
protocol, extended phenotyping is performed in a subset
of patients (see below). All procedures are performed
according to standard operating procedures. Adherence to
these are ensured by regular training and internal
audits. The DIACORE Study Group (see Appendix
for current full member list) devises scientific analyses in
the DIACORE study.
DIACORE is one of five cohort studies co-funded by the
Kuratorium für Dialyse und Nierentransplantation (KfH)
Foundation for Preventive Medicine e.V. The other cohorts
are recruiting 5000 patients with CKD stage 3 or overt
proteinuria to investigate CKD progression and associated
complications [35], 2000 elderly individuals to establish a
GFR estimation equation specific for the elderly [36], 625
children with CKD to investigate mechanisms involved in
accelerated atherosclerosis [37] and 3000 patients after cor-
onary angiography to investigate the relationship between
coronary artery disease and CKD (CAD-REF registry). All 5
cohorts have harmonized their data protection standards
(see below), the questionnaire and central laboratory
parameters (http://www.kfh-stiftung-praeventivmedizin.de).
Inclusion criteria
Inclusion criteria are the ability to provide written informed
consent, age ≥18 years, self-reported Caucasian ethnicity
and prevalent diabetes mellitus type 2. Diabetes mellitus
type 2 is defined as need for blood glucose lowering medi-
cation, at least two measurements of fasting glucose ≥126
mg/dL or a 2-hour glucose value in OGTT >200 mg/dL
[38-40]. Criteria for diagnosis of diabetes mellitus type 2 are
obtained by self-report or from clinical records obtained
from the patients’ health care provider.
Exclusion criteria
Patients are excluded if, at baseline, they are on chronic
renal replacement therapy (hemodialysis, peritoneal dialysis
or transplantation), if, at baseline, there is a history of active
malignancy (except those with basal cell carcinoma)
within the last five years (prostatic cancer within the
last two years), autoimmune disease potentially affecting
kidney function (e.g. systemic lupus erythematodes),
hemochromatosis, history of pancreoprivic or self-reported
type 1 diabetes mellitus, acute infection or fever, pregnancy,
chronic viral hepatitis or HIV-infection.
Patient ascertainment
All DM2 patients aged at least 18 years living in the region
around the study centers are invited to participate. To
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diabetologists, general practitioners and health insurance
companies send written invitations, the study flyer and a
stamped return post card to all DM2 patients in their
records. Where permitted by the local diabetologist,
DIACORE study personnel ascertains patients in the
diabetologist’s office. Further, all DM2 patients without
cancer (i.e. excluding patients with ICD-9 codes 140–239
or ICD-10 codes C00-C97) previously treated in each of
the study center’s Departments of Internal Medicine aged
at least 18 years and living in the region surrounding the
recruiting center are invited by the local study center. All
activities involving mailing of written invitations are
flanked by supportive press releases. Patients are asked to
reply by telephone or to use a stamped return post card in
order to arrange an appointment with the study center for
recruitment into DIACORE. Further, diabetologists and
general practitioners are asked to distribute DIACORE
study flyers to their patients in the doctor’s office.
Core phenotyping protocol
Physical examination
The parameters of the physical examination are shown
in Additional file 1: Table S1. Heart rate and blood pres-
sure are assessed using a vital signs monitor after the
patient has been seated for a five minute period. Three
measurements are then performed every 2 minutes. The
second and third measurements of blood pressure and the
third measurement of pulse are recorded. Anthropometric
parameters are measured in light clothing without shoes
and after removal of any items from pockets. Weight is
measured in kilograms with one decimal using a digital
scale. Height is registered in centimeters standing face
forward and shoeless, using a wall-mounted stadiometer.
Waist and hip circumference are measured in centimeters
using a 205 cm tape in a horizontal position by trained
study nurses. The wearing of light clothing is recorded for
adjustment in the online questionnaire [41]. The waist
measuring point is defined as the smallest circumference
between the upper iliac crest and lower costal margin. If
this cannot be determined, e.g. in obese patients, the mea-
surement is taken at the midway point between the upper
iliac crest and lower costal margin. Hip circumference is
measured at the largest circumference below the iliac crest
over the trochanter major and over the buttocks.
Online questionnaire
After the physical examination and the taking of blood
samples, patients are administered an online standardized
questionnaire by trained study nurses (electronic case
report form, eCRF), which assesses ethnicity, medical
insurance status and participation in disease management
programs, physical activity, nicotine and alcohol
consumption, nephrological and urological history,cardiovascular risk factors and complications, medi-
cation, hospitalization and cancer history (Table 1).
Further, information is obtained on how the patient
first heard of the DIACORE study.
Biosampling
Whole blood samples are drawn after the patients have
rested in a seated position for at least 15 minutes, applying
mild venous stasis and using a 21G butterfly needle
(Sarstedt), into serum gel, EDTA, sodium fluoride (all
Sarstedt, Germany) and PaxgeneW tubes (PreAnalytix
GmbH, Switzerland). At the end of the interview, the
patient is asked to provide a spot midstream urine sample
into a sterile 100 mL cup (Sarstedt, Germany). A urine
dipstick (Combur, Germany) is performed in the fresh urine
sample within 15 minutes after donation for quality
assurance (erythrocyturia, leukocyturia and nitrite)
and for semiquantitative determination of proteinuria.
Blood and urine sample processing follows identical
standard operating procedures in all recruiting centers: All
samples are kept at room temperature for 30 minutes, then
all blood and urine tubes except the EDTA and sodium
fluoride tubes for whole blood count, HbA1c, DNA isola-
tion and blood glucose determination are centrifuged at
2500 G for 10 minutes, after which a 2mL urine sample is
transferred into a sterile polyethylene tube, with subse-
quent storage of all samples at 4°C until further processing.
A centrifuged serum gel tube, an EDTA anticoagulated
whole blood tube, the sodium fluoride anticoagulated
blood tube and the 2 mL urine sample are packaged for
delivery to the central laboratory for determination of a
standard clinical chemistry panel while a 500 μL serum
sample is frozen at −20°C until batch transport to the
central laboratory for measurement of insulin activity
(Additional file 1: Table S2). After 2–4 hours, all remaining
serum and urine, and 2mL EDTA-plasma are aliquoted
into 2D barcoded polypropylene tubes for long-term
storage in −80°C freezers at each of the recruiting centers
with electronic temperature monitoring. The archiving of
the 2D barcoded tubes is done within the eCRF using an
integrated software module (BioArchive, MEDEORA
GmbH; Köln, Germany). The PaxgeneW tube is handled
according to the instruction provided by the producer
before being transferred for long term storage at −80°C.
Uncentrifuged EDTA-anticoagulated whole blood is stored
at −80°C until DNA isolation, which is performed centrally
at the University of Regensburg using a Qiagen kit.
Clinical chemistry panel
A clinical chemistry panel is obtained from every patient
at every visit in a central laboratory using state of the art
analyzers (Additional file 1: Table S2). Blood samples are
transported weekdays at a temperature range of 4-8°C
from recruiting centers to the central laboratory, except
Table 1 Core phenotyping in DIACORE
Phenotype
category
Item Instrument for obtaining
phenotype






















































Time to doubling of
serum creatinine
L§
Time to incident renal
replacement therapy
Q#§




History of malignancy Q#
Hospitalisation Q#§
Mortality including cause Q#§
CAD: Coronary artery disease. PAD: peripheral artery disease. Q: self-reported
information obtained by questionnaire. L: obtained by laboratory analysis of
biosamples. P: obtained by physical examination.
* item determined at baseline visit only.
# items validated by obtaining medical records.
§ item determined at follow-up visits only.
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batches on dry ice. Surveillance of temperature during
transport is performed at regular intervals.
Report of examination results to patients
Feedback to the patient is provided in the case of
severely abnormal results (blood pressure > 180 mmHg
systolic and 110 mmHg diastolic or < 90 mmHg systolic
and 50 mmHg diastolic ; Pulse > 90/min and < 50 /min
or irregular) at the end of the examination. Participants
with abnormal results are either referred to the appro-
priate health care provider or, in medical emergencies,
brought to the emergency room for further assessment.
A written report including results of the physical
examination and of the standard laboratory panel is
mailed to the patient who is asked to appropriately
inform their primary health care provider as previously
reported [36]. Each parameter is reported with age and
gender specific reference values.
Follow-up examination
Follow-up examinations are performed every two years
with the same standard operating procedures applied as at
baseline. At each of these examinations, the manifestation
of phenotypes listed in Table 1 since the last examination
is recorded, including their date of manifestation to
determine the time of onset.
Clinical outcomes
Clinical outcomes (Table 1, category “Morbidity”) are
assessed at baseline (for cross-sectional analyses) and
at each follow-up (for longitudinal analyses). Several
phenotypes are defined by laboratory parameters
(Additional file 1: Table S2). For example, kidney function
is defined by estimating the GFR (eGFR) from a serum
creatinine or cystatin C measurement [42-46] and the
CKD status is derived from eGFR. Similarly, the degree of
albuminuria is determined from the albumin-creatinine
-ratio in the random spot urine.
The clinical end points are validated at every visit
including the baseline visit by the DIACORE end point
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tation is requested up to three times from the patients’
treating physicians, and subsequently assessed indepen-
dently by the members of the end point committee. If the
verdict of the two members does not match, then agree-
ment is sought by joint consultation. If a patient-reported
end point cannot be confirmed by available documentation
or if adequate medical documentation is not available, then
that end point is coded as “not validated”. Thus, the
validated end points form a subset of the overall set
of self-reported end points.
Extended phenotyping
DIACORE is open to ancillary studies to extend the
current core phenotyping panel. Planned ancillary studies
entail more intense phenotyping in a random subset of
patients, e.g. screening for sleep apnea syndrome,
non-mydriatic retinal photography, measurements of
skin autofluorescence and arterial stiffness parameters.
Power considerations
The calculation of DIACORE’s planned sample size of
6000 DM2 patients is based on estimations for renal
events made in the UKPDS study [47]: after approximately
10 years with DM2, 25% of patients had developed
increased urinary albumin excretion (microalbuminuria),
about 2-3% of patients progressed each year from normal-
buminuria to macroalbuminuria and then reduced eGFR
or ESRD, and annual mortality rate increased from 1.2 to
4.6% as patients progressed from normalbuminuria to
macroalbuminuria. Loss to follow up was on average 1%
per year [47].
Within the fifth year we expect to have recruited a
cohort of 6000 participants. Based on the estimations
made by Adler et al. [47] but assuming a more conserva-
tive drop out rate of 5% per year and a mortality rate of
4% per year, 750 (12.5%) participants will be lost to
follow up and 600 (10%) will have died after the five years.
We estimate that 1500 patients (25%) will have baseline
microalbuminuria and that after 5 years 375 (6.25%) will
develop microalbuminuria, macroalbuminuria, incident
eGFR<60 ml/min/1.73 m2 or ESRD respectively, thus pro-
viding DIACORE with sufficient cases for cross-sectional
and longitudinal analyses.
Data handling and protection
DIACORE constitutes a human biomaterial databank
with implications for protection of individual patient
data. At baseline assessment every participant receives a
pseudonym ID. Personal information such as name and
address is stored separately. All information gathered
from the online questionnaire is stored in an online elec-
tronic case report form (Sapphire, MEDEORA GmbH;
Köln, Germany) under a second pseudonym ID which istransformed from the first pseudonym ID by a commer-
cial online provider. Transmission of data is encrypted
using a 256bit-SSL standard.
The data protection strategy is based on the generic
model of the “platform for technology and methods for
networked medical research” (TMF e.V., www.tmf-ev.de)
supported by the German Ministry of Education and
Research. A subset of the parameters obtained by
questionnaire and by central laboratory testing is
transferred to a central database which pools data
from all five studies co-funded by the KfH Foundation for
Preventive Medicine.
Ethical approval and informed consent
The protocol, the data protection strategy and the study
procedures have been approved by the Ethics Committees
of participating institutions and are in accordance with the
Declaration of Helsinki. Patients participate in DIACORE
only after providing informed written consent.
Discussion
The DIAbetes COhoRtE (DIACORE) study is a large
cohort of prevalent DM2 patients in Germany that started
recruitment in February 2010 for long term prospective
observation with follow-up examinations every 2 years.
DIACORE aims to elucidate novel mechanisms involved in
the development of DM2 complications with a focus on
diabetes-associated kidney disease. To achieve this, standar-
dized phenotyping is being performed every 2 years, with
biobanking of serum, plasma, DNA, mRNA and urine for
future scientific analyses. All procedures are standardized
for collaborative projects with population-based [30,31] and
disease-based cohorts [35,36]. Due to its size and prospec-
tive design, DIACORE is an important extension to the
current worldwide repertoire of DM2 cohorts of Caucasian
descent investigating diabetes complications [15,48-51] and
the first of comparable size in Germany.
DIACORE aims to recruit a representative sample of
outpatient, ambulating DM2 patients in Germany. We
have adopted a strategy of addressing eligible patients
via several channels to achieve this aim: 1) a wide range
of public communication media including local press
and patient organisations, 2) major health insurance
companies, 3) all general practitioners and 4) all diabetes
specialists in a defined geographic region. Once the
cohort is recruited, comparisons with the DM2 subsets
of large population-based cohorts [4,5,52,53] and with
data from German diabetes disease management data
bases will serve to assess potential bias.
We have purposefully avoided using the term “diabetic
nephropathy” to describe renal outcomes in DIACORE
since a clinical diagnosis of diabetic nephropathy based
only on proteinuria, eGFR and history is subject to mis-
classification if a kidney biopsy is not performed [54-57]:
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detected in about 23-33% of DM2 patients with macro-
albuminuria. Further, it has been shown in DM1 and
DM2 patients that a substantial proportion of DM
patients develop decreased eGFR without concurrent or
prior elevation of albuminuria [58-62], suggesting an under-
lying non-diabetic kidney disease such as hypertension-
associated nephrosclerosis. In addition, genetic studies have
demonstrated disparate genetic underpinnings for albumi-
nuria and eGFR in both the general population and in
diabetes patients [21,25,27,63]. Taken together, these data
support the concept of separate analyses of these traits.
DM2 incidence and prevalence is increasing in
industrialized countries. In addition to the disease
itself, its complications are a major public health and
financial challenge. Thus, the investigation of factors
involved in the development and progression of diabetic
complications, including CKD, is essential to develop
novel strategies for prevention and therapy.
An innovative approach for uncovering mechanisms
underlying common diseases includes unbiased high-
throughput screening of biomaterials using methods
such as genome-wide association studies (GWAS)
[29], and complementary analyses of the metabolome,
transcriptome and proteome [64,65]. This approach
has the advantage of a systematic analysis without
prior biological hypothesis, thus bearing the potential of
uncovering unexpected and completely novel mechanisms
of disease. In this sense, GWAS have been successful for
the majority of common diseases [66] including DM2 and
chronic kidney disease (CKD). For example, UMOD, the
gene encoding Uromodulin or Tamm-Horsfall-Protein, is
among the loci associated with CKD [24,26,27,67,68]. This
protein has long been known to be the quantitatively most
important protein in human urine, but its function is
unknown. Research is now focusing on the mechanisms
involved in affecting this established association with risk
for CKD in the general population [69].
In contrast, genetic variants associated with DM2-
associated kidney disease have not consistently been
replicated [28], possibly owing to lack of sufficient power
either due to low sample size or to the small effects of
genetic variants in common disease. Though DIACORE
will be one of the largest DM2 cohorts of European
descent, power may not be sufficient for detecting
genetic variants with small effects sizes. However, since
DIACORE’s study protocol is standardized for colla-
borative projects with other cohorts, joint meta-
analysis is an excellent option for increasing power.
Pooling data from several studies in international
collaborations such as the CKDGen consortium has
been successful in the past in analyzing the genetic
underpinning of kidney phenotypes in the general
population [24,25,27,68].The strengths of the DIACORE study include its large
size, prospective design, rigorous protocol standardization,
centralized data management and excellent pre-analytics in
biosample archiving. There are limitations that warrant dis-
cussion. As management of diabetes and its complications
has improved significantly since publication of the study
that our power calculation is based on [47], event rates in
DIACORE may be lower than expected. However, the
projected sample size makes DIACORE one of the largest
DM2 cohorts world wide. Furthermore, bias may arise due
to our recruitment strategy, but DM2 patients are
addressed repeatedly along multiple channels in the same
geographic regions thus providing broad feed back among
the targeted population of ambulating DM2 patients. In
addition, the questionnaire is designed to help quantify any
recruitment bias. We cannot exclude or quantify a poten-
tial, small effect on outcomes caused by reporting the
laboratory and physical examination results to patients.
However, this reporting is an imperative medical duty to
volunteering patients. Finally, urinary albumin excretion is
estimated from one spot urine sample as it is logistically
unfeasible to collect the recommended three urine samples.
To compensate this drawback, dipstick testing on fresh
urine is performed to exclude urinary tract infection, and
the time at which urine is donated is recorded.
In summary, DIAbetes COhoRtE (DIACORE) is a cohort
study with a biosample repository aiming to recruit 6000
prevalent diabetes mellitus type 2 patients of Caucasian
descent in Germany for long term prospective observation
with follow-up examinations every 2 years. Main aims are
to discover novel mechanisms involved in developing
kidney disease and cardiovascular morbidity among
diabetes patients, using systematic genetic and biomarker
analyses. In the long-term, DIACORE aims to provide
impetus for the development of novel strategies in the
prevention and treatment of DM2 complications.
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